Cancer Grant

Recipients

Carmen

Bergom,

M.D., Ph.D.

2017

Milwaukee,

WI

Medical College of Wisconsin

Identifying Genetic Factors that Decrease Side Effects and Enhance the Efficacy of Breast Cancer Radiation

Susann

M.

Brady-Kalnay

2017

Cleveland,

OH

Case Western Reserve University School of Medicine

PTPμ as a targeting agent for ultrasound-enhanced treatment of ovarian cancer

Sidi

Chen

2017

New Haven,

CT

Yale University

Identifying novel non-coding biomarkers for ovarian cancer metastasis

Anthony

Faber

2017

Richmond,

VA

Virginia Commonwealth University

A major cause of HER2i resistance in HER2-amplified breast cancer and a therapeutic combination to overcome it

Katherine

Fuh,

M.D., Ph.D.

2017

St. Louis,

MO

Washington University

Predictive Kinome for Treatment of Chemo resistant Ovarian Cancer

Melissa

Herbst-Kralovetz,

Ph.D.

2017

Phoenix,

AZ

University of Arizona, Phoenix

Elucidating the Genital Microbiome and Local Immune Microenvironment in Endometrial Cancer Patients

Manabu

Kurokawa,

Ph.D.

2017

Hanover,

NH

Geisel School of Medicine at Dartmouth

Targeting the fatty acid transporter CD36 in HER2 positive breast cancer

Michael

Pacold

2017

New York,

NY

New York University School of Medicine

Targeting serine metabolism in breast cancer

Ali

Shilatifard

2017

Chicago,

IL

Northwestern University Feinberg School of Medicine

Therapeutic targeting of SET1B/COMPASS pathway in treating triplenegative breast cancer

Fiona

Simpkins

2017

Philadelphia,

PA

University of Pennsylvania

Circumventing drug resistance in CCNE1 amplified ovarian cancer

Jiangbin

Ye

2017

Stanford,

CA

Stanford University

Targeting serine and one-carbon unit metabolism in metastatic breast cancer

Qing

Zhang

2017

Chapel Hill,

NC

University of North Carolina at Chapel Hill

Hairless (HR) as a Novel Therapeutic Target in Basal-Like Breast Cancer

Ross

Cagan,

M.D.

2016

New York,

NY

Icahn School of Medicine at Mount Sinai

Drosophila Models of Triple Negative Breast Cancer as a Platform to Identify Novel Therapeutics

Ronald

Chandler,

Ph.D.

2016

East Lansing,

MI

Michigan State University, College of Human Medicine

SWI/SNF chromatin remodeling and Pl3-kinase pathway crosstalk mechanisms in ovarian cancer

Jack

E.

Dixon,

M.D.

2016

La Jolla

CA

University of California San Diego

DYRK2, a novel therapeutic target for Triple-Negative Breast Cancer

Hui

Feng,

Ph.D.

2016

Boston,

MA

Boston University School of Medicine

Targeting Elevated S1P1 Signaling as a Novel Therapeutic Approach for Triple-Negative Breast Cancer

Michael

Flister,

M.D.

2016

Milwaukee

WI

West Medical College of Wisconsin

Role of Tumor-Host Crosstalk in Genetic Evolutionary Response of Breast Cancer

Hamid

Mirzaei,

M.D.

2016

Dallas,

TX

UT Southwestern Medical Center

Developing a high-resolution SRM-based diagnostic platform for breast cancer subclinical diagnosis and personalized therapy

Raymond

E.

Moellering,

M.D.

2016

Chicago,

IL

University of Chicago Comprehensive Cancer Center

Precision imaging diagnostics to detect and target metastatic progression in breast and ovarian cancer

Richard

G.

Moore,

M.D.

2016

Rochester,

NY

University of Rochester

The Role of HE4 in Immunity, Chemotaxis and Immune Dysfunction in Ovarian Cancer

Aydogan

Ozcan,

M.D.

2016

Los Angeles,

CA

UCLA David Geffen School of Medicine

Automated Pap smear Testing using a Field-Portable and Cost-effective Lensfree Computational Microscopy Platform

Richard

T.

Pomerantz,

Ph.D.

2016

Philadelphia,

PA

Temple University School of Medicine

Targeting DNA Polymerase for Precision Medicine in BRCA Deficient Cancers

Erinn

B.

Rankin,

M.D.

2016

Palo Alto,

CA

Stanford

Hypoxic Signaling in Tumor Metastasis: Molecular Mechanisms and Targeted Therapy

David

A.

Spiegel,

M.D.

2016

New Haven,

CT

Yale University

Enhancing Immune Recognition of Breast Cancer Using Small Molecules

Nikhil

Wagle

M.D.

2016

Boston,

MA

Harvard Medical School

Elucidating Mechanisms of Intrinsic and Acquired Resistance to Combined ER and CDK4/6 Inhibition in Metastatic Breast Cancer

Mekhail

Anwar,

Ph.D.

2015

San Francisco,

CA

University of California, San Francisco

The Development of a Microfabricated Fluorescent Imager for Real-Time, Intraoperative Imaging of Microscopic Residual Disease in Breast Cancer

Lewis

A.

Chodosh,

Ph.D.

2015

Philadelphia,

PA

Trustees of University of Pennsylvania

Mechanisms of breast cancer dormancy and recurrence

Roisin

Connolly,

Ph.D.

2015

Baltimore,

MD

Johns Hopkins Univ. SOM

Harnessing the immune system to treat breast cancer: Novel mechanisms of resistance and treatment strategies

Brooke

M.

Emerling,

Ph.D.

2015

New York,

NY

Joan & Sanford I. Weill Med. College of Cornell University

Targeting p53 mutant breast cancers through inhibition of the Phosphatidylinositol-5 Phosphate 4 Kinases

Steven

Frisch,

Ph.D.

2015

Morgantown,

WV

West Virginia University Research Corp.

Suppression of Breast Cancer Recurrence

Michael

R.

Green,

Ph.D.

2015

Wocester,

MA

University of Massachusetts Medical School

Understanding and Predicting Therapeutic Responsiveness in Ovarian Cancer

Edward

J.

Gunther,

M.D.

2015

Hershey,

PA

Penn State College of Medicine

Genetic Dissection of Breast Cancer Metastasis Using Time-Stamped Transposon Mutagenesis

Michael

Karin,

Ph.D.

2015

La Jolla,

CA

University of California, San Diego

Tackling Breast Cancer Metastasis by Targeting Ubiquitination-Mediated Signaling Pathways

Todd

W.

Miller,

Ph.D.

2015

Lebanon,

NH

Geisel School of Medicine at Dartmouth

Mechanisims underlying doormancy in ER+ breast cancer

Dohun

Pyeon,

Ph.D.

2015

Aurora,

CO

University of Colorado Denver

Targeing Chemokine Expression in the Tumor Microenvironment to Suppress Cervical Cancer Progression

Rosa

Ana

Risques,

Ph.D.

2015

Seattle,

WA

University of Washington

Early detection of ovarian cancer by ultra-sensitive sequencing of Pap smear DNA

Daniel

J.

Siegwart,

Ph.D.

2015

Dallas,

TX

UT Southwestern Medical Center

Dendritic Lipid Nanoparticle (DLNP)-mediated miRNA Delivery to Treat Ovarian Cancer

Rong

Xu,

Ph.D.

2015

Cleveland,

OH

Case Western Reserve University Medical School

Combining a novel computational drug repositioning approach with clinical and biological testing for rapid epithelial ovarian cancer druge discovery

Thomas

P.

Ahern,

Ph.D.

2014

Burlington,

VT

University of Vermont College of Medicine

Predictive biomarkers of breast tumor response to statin therapy

Carey

K.

Anders,

Ph.D.

2014

Chapel Hill,

NC

University of North Carolina-Chapel Hill SOM

Targeting The P13K and MEK Pathways in Triple Negative Breast Cancer Brain Metastases

Luis

A.

Diaz,

M.D.

2014

Baltimore,

MD

Johns Hopkins University

A molecular pap smear for the detection of ovarian and endometrial cancers

Mohit

Jain,

Ph.D.

2014

La Jolla,

CA

University of California, San Diego

Targeting Cancer-Specific Metabolic Activity for Breast Cancer Therapy

Carol

A.

Lange,

Ph.D.

2014

Minneapolis,

MN

University of Minnesota

PTK6 Drives Metastasis in Therapy-Resistant Triple-Negative Breast Cancer

Yi

Li,

Ph.D.

2014

Houston,

TX

Baylor College of Medicine

Intermittent rusolitinib treatment for preveiton of breast cancer in nulliparous women

Laurie

Littlepage

Ph.D.

2014

South Ben,

IN

University of Notre Dame

Overcoming Breast Cancer Chemoresistance Using ZNF217 as a Prognostic Marker and Therapeutic Target

Vivek

Mittal,

Ph.D.

2014

New York,

NY

Joan & Sanford I. Weill Medical College of Cornell University

Pharmacological targeting of the Polycomb Frepressive Complex 2 impairs breast cancer metastasis

Melissa

Skala,

Ph.D.

2014

Nashville,

TN

Vanderbilt University

A New Paradigm for Drug Development and Treatment Planning in Breast Cancer

Yihong

Wan,

Ph.D.

2014

Dallas,

TX

UT Southwestern Medical Center

A Novel Strategy to Inhibit Bone Metastasis of Breast Cancer

Adam

de la

Zerda

Ph.D.

2014

Palo Alto,

CA

Stanford University

MOZART: A New Breast Cancer Duagnostic Technology for Single Cell Imaging In Vivo

Peter

Zhou,

Ph.D.

2014

Lexington,

KY

University of Kentucky

Dissectingthe critical Functions of theDub3-Snail Axis in Basal-like Breast Cancer

David

K.

Ann,

Ph.D.

2013

Duarte,

CA

City of Hope

Targeting Arginine Dependency, a Metabolic Achilles' Heel for Breast Cancer

Alexander

S.

Brodsky,

Ph.D.

2013

Providence,

RI

Brown University

New Approaches to Target Mevalonate Biosynthesis for Ovarian Cancer

Kathleen

Cho,

M.D.

2013

Ann Arbor,

MI

The University of Michigan

Examining falopian tube origin of high grade serous "ovarian" carcinoma

Dipanjan

Chowdhury,

Ph.D.

2013

Boston,

MA

Dana-Farber Cancer Institute

MicroRnas as a Molecular Basis for Defective Homologous Recombination in Epithelial Ovarian Cancer

Analisa

DiFeo,

Ph.D.

2013

Cleveland,

OH

Case Western Reserve University Sch. of Medicine

Single Agent Dual Inhibition of the AKT and ERK Signaling Pathway for the Treatment of Ovarian Cancer

Andrew

J.

Ewald,

Ph.D.

2013

Baltimore,

MD

Johns Hopkins University

Basal marker+ cancer cells lead collective invasion and dissemination across multiple subtypes of breast cancer

Liza

Makowski,

Ph.D.

2013

Chapel Hill,

NC

University of North Caroline at Chapel Hill

Reversing carcinogenic effect of obesity on basal-like breast cancer

Michael

G.

Rosenfeld,

M.D.

2013

La Jolla,

CA

University of California, San Diego

Reprogramming Breast Cancer Cells

Joy

Y.

Wu

Ph.D.

2013

Stanford,

CA

Stanford University Sch. of Med.

Effects of Parahyroid Hormone on the Breast Cancer Metastatic Niche in Bone

Gerburg

M.

Wulf,

Ph.D.

2013

Boston,

MA

Beth Israel Deaconess Medical Center

Use of P13Kinase inhibitors to improve the Outcomes of Antineoplastic Treatments for Breast Cancer

Jacob

Berlin,

Ph.D.

2012

Duarte,

CA

City of Hope

Stem Cell-Mediated Targeted Therapy for Triple Negative Breast Cencer

Alfred

L. M.

Bothwell,

Ph.D.

2012

New Haven,

CT

Yale University

Modeling of Human Immune System Interaction with Breast Tumors and Treatments in Mice

Rolf

A.

Brekken,

Ph.D.

2012

Dallas,

TX

UT Southwestern Medical Center

ALK as a driver of breast cancer metastasis

Eric

C.

Chang,

Ph.D.

2012

Houston,

TX

Baylor College of Medicine

N-Ras as a key regulator and potential treatment target for basal-like breast cancer

Gerald

R.

Crabtree,

M.D.

2012

Stanford,

CA

Stanford University

Targeting Ovarian Cancer via Cooperative Oncogene Interactions

Paloma

H.

Giangrande,

Ph.D.

2012

Iowa City,

IA

University of Iowa

Multifunctional RNA-based Reagents for the Treatment of Ovarian Cancer

Andrew

K.

Godwin,

Ph.D.

2012

Kansas City,

KS

University of Kansas Medical Center

High-Throughput Microfluidic Exosome Profiling Platform for Early Detection of Ovarian Cancer

William

Hahn,

Ph.D.

2012

Boston,

MA

Dana-Farber Cancer Institute

Genomic Characterization of Brain Metastases from Breast Cancer

David

Sherr,

Ph.D.

2012

Boston,

MA

Trustees of Boton University, BUMC

A Novel AhR-Targeted Therapeutic for Triple Negative and Chemo-Resistant Breast Cancers

Barry

Sleckman,

Ph.D.

2012

St. Louis,

MO

Washington University

Identification of Novel DNA double strand break repair targeting therapeutics for the treatment of breast cancer

LuZhe

Sun,

Ph.D.

2012

San Antonio,

TX

The University of Texas Health Science Center at San Antonio

Bisphenol A and Breast Cancer -- Effect on Mammary Stem Cell and its Niche

John

J.

Turchi,

Ph.D.

2012

Indianapolis,

IN

Indiana University

Rational, biology-based combination therapy for the treatment of ovarian cancer

Deric

L.

Wheeler,

Ph.D.

2012

Madison,

WI

Board of Regents of the University of WI System

Targeting nuclear EGFR: Strategies for improving cetuximab therapy in triple-negative breast cancer

Emily

Bernstein,

Ph.D.

2011

New York,

NY

Mount Sinai School of Medicine

Identifying Epigenetic Drivers of Breast Cancer

Kenneth

L.

Bost,

Ph.D.

2011

Charlotte,

NC

University of North Carolina at Charlotte

A viral infection that exacerbates breast cancer mestastasis

Martina

J.

Cannon,

Ph.D.

2011

Little,

AR

University of Arkansas

Dendritic cell activation of therapeutic Th17 responses against ovarian cancer

Jeanette

G.

Cook,

M.D.

2011

Chapel Hill,

NC

The University of North Carolinal at Chapel Hill

Predicting genone instability in breast cancer

Yan

Dong,

Ph.D.

2011

New Orleans,

LA

Tulane University School of Medicine

Improving the therapeutic outcome for triple-negative breast cancer by restoring normal function to mutant p53

Kevin

R.

Kozak,

Ph.D.

2011

Madison,

WI

University of Wisconsin School of Medicine U Public Health

Rational Molecular Multi-targeting in Hormone Receptor-Positive Breast Cancer

Ruth

Lupu,

Ph.D.

2011

Rochester,

MN

Mayo Clinic

Fatty acid Synthase (FASN): Molecular Target for Breast Cancer Therapy

David

Lyden,

Ph.D.

2011

New York,

NY

Joan & Sanford I. Weill Medical of Cornell University

The role of bone marrow-derived progenitor cells and tumor emboli-derived exosomes in malignant progression of IBC

Sanaz

Memarzadeh,

Ph.D.

2011

Los Angeles,

CA

Regents of the University of California, Los Angeles

Mechanisims and predictors of response to progesterone therapy in endometrial carcinoma

Gray

W.

Pearson,

Ph.D.

2011

Dallas,

TX

UT Southwestern Medical Center

Investigating the non-cell autonomous regulation of breast cancer metastasis

Thomas

Szyperski,

Ph.D.

2011

Buffalo,

NY

University at Buffalo Foundation Services

Non-invasive diagnosis of early state ovarian cancer by 1H-NMR of blood serum

Zeng-Quan

Yang,

Ph.D.

2011

Detroit,

MI

Karmanos Cancer Institute

Targeting histone demethylases as a theerapeutic-strateby in basal breast cancer

Richard

Baer,

Ph.D.

2010

New York,

NY

Columbia University Medical Center

Which functions of BRCA1 suppress breast cancer:

Mark

E.

Burkard,

Ph.D.

2010

Madison,

WI

University of Wisconsin- Madison

Identifying synthetic lethal approaches targeting polyploidy in human breast cancer

Ronny

Drapkin,

Ph.D.

2010

Boston,

MA

Dana-Farber Cancer Institute

Defining the role of the fallopian tube secretory epithelial cell in the pathogenesis of serous ovanian carcinoma

Edward

Gunther,

M.D.

2010

Hershey,

PA

Pennsylvania State College of Medicine

Dissecting Mammary Cell Lineage-specific Signaling Pathway

Richard

N.

Kitsis,

M.D.

2010

Bronx,

NY

Albert Einstein College of Medicine of Yeshiva University

Mechanistic Role of Necrosis - Not Apoptosis - in Breast Cancer

Lawrence

Lum,

Ph.D.

2010

Dallas,

TX

UT Southwestern Medical Center

Targeting the cancer stem cell compartment in breast and cervical cancer using novel tankyrase inhibitors

Martina

M.

Matzuk,

Ph.D.

2010

Houston,

TX

Baylor College of Medicine

Novel microRNA Therapies for Ovarian Cancer

Rita

Nahta,

Ph.D.

2010

Atlanta,

GA

Emory University

Growth Differentiation Factor 15, a novel mediator of trastuzumab resistance in HER2-overexpressing breast cancer

Roel

Nusse,

Ph.D.

2010

Stanford,

CA

Stanford University

Genes for self-renewal of normal and tumor breast stem cells

Sandra

Ryeom,

Ph.D.

2010

Philadelphia,

PA

University of Pennsylvania School of Medicine

Role of the Platelet Angiogenic Proteome in Cervical Cancer

Frank

Slack,

Ph.D.

2010

New Haven,

CT

Yale University

A microRNA binding site mutation in KRAS and risk of hereditary breast and ovarian cancer

Elizabeth

Swisher,

M.D.

2010

Seattle,

WA

University of Washington

BRCA1/2 Restoration as a Predictor in a GOG Clinical Trial for Recurrent Ovarian Carcinoma

Angelique

W.

Whitehurst,

Ph.D.

2010

Chapel Hill,

NC

The University of North Carolina at Chapel

Defining a Funcational Signature of Chemosensitivity in Ovarian Cancer Subtypes

Eric

J.

Brown,

Ph.D.

2009

Philadelphia,

PA

University of Pennsylvania

Treatment of ovarian and breast cancers through partial inhibition of the DNA replication checkpoint.

Viyakrishna

K.

Gadi,

M.D., Ph.D.

2009

Seattle,

WA

Fred Hutchinson Cancer Research Center

Fetal Microchimerism in Breast Cancer

Paloma

H.

Giangrande,

Ph.D.

2009

Iowa City,

IA

The University of Iowa

Multifunctional Aptamer-siRNA Chimeras Targeting EphA2 Expressing Breast Cancers

Kevin

A.

Janes,

Ph.D.

2009

Charlottesville,

VA

The Rector and Visitors of the University of Virginia

Mechanism of a TGFBR-JUND single cell dichotomy and its role in breast tumorigenesis

Paul

F.

Lambert

Ph.D.

2009

Madison,

WI

The Board of Regents of the Universtiy of Wisconsin System

A New Therapy for Cervical Cancer: Preclinical Studies

Mark

Moasser,

M.D.

2009

San Francisco,

CA

University of California, San Francisco

Breaking the HER3 barrier in the treatment of HER2-amplified breast cancer

Lynne

Regan,

Ph.D.

2009

New Haven,

CT

Yale University

Development of a Novel Class of Hsp90 Inhibitors as anti-Cancer Therapeutics

Julie

Schwarz,

M.D., Ph.D.

2009

St. Louis,

MO

Washington University

Targeting the premetastatic niche in cervical cancer

Philip

W.

Shaul,

M.D.

2009

Dallas,

TX

Univ. of Texas Southwesten Medical Center

Breast cancer modulation by 27-hydroxycholesterol, the first identifed endogenous SERM

Jose

M.

Silva,

Ph.D.

2009

New York,

NY

Columbia University

Genetic synthetic lethality: Genetics approaches for personalized breast cancer therapy

Thomas

Westbrook,

Ph.D.

2009

Houston,

TX

Baylor College of Medicine

Discovering therapeutic targets for breast cancer with new technologies

Jing

Yang,

Ph.D.

2009

La Jolla,

CA

University of California, San Diego

Dissecting the transcription network in breast tumor metastasis

Binhua

Zhou,

Ph.D.

2009

Lexington,

KY

University of Kentucky School of Medicine

Dissecting the dysregulaiton of epithelial-mesenchymal transition at breast cancer metastasis

Nita

Ahuja,

M.D.

2008

Baltimore,

MD

John Hopkins University

Molecular Staging of Breast Cancer Using Methylation Profiles

Steven

J.

Altschuler,

Ph.D.

2008

Dallas,

TX

UT Southwest Medical Center

Relating Ovarian Cancer Cell Phenotypes to Drug Sensitivities

James

Basilion,

Ph.D.

2008

Cleveland,

OH

Case Western Reserve University

Molecular imaging for ex vivo identification of tumor margin infiltrates in resected breast cancers

Brian

P.

Ceresa,

Ph.D.

2008

Oklahoma City,

OK

University of Oklahoma Health Sciences Center

HPV16 E5 Mediated Cell Fusion in Oncogenesis

Vincent

L.

Cryns,

M.D.

2008

Chicago,

IL

Northwestern University

Cancer stem cell-targeted therapies for breast cancer

Ekaterina

Dadachova,

Ph.D.

2008

Bronx,

NY

Albert Einstein College of Medicine

Targeting viral antigens with radiolabeled antibodies as a novel approach to treatment of cervical cancer

Daniela

Dinulescu,

Ph.D.

2008

Boston,

MA

Brigham and Women's Hospital, Harvard Medical School

Chemoresistance to therapy in ovarian cancer: role of cancer stem cells

Nathanael

S.

Gray,

Ph.D.

2008

Boston,

MA

Dana-Farber Cancer Institute

Pharmacological validation of FGFR as a target for the treatment of breast cancer

Roger

A.

Greenberg,

M.D., Ph.D.

2008

Philadelphia,

PA

University of Pennsylvania

Systematic identification of breast cancer susceptibility gene candidates within the BRCA1 tumor suppressor network

Rong

Li,

Ph.D.

2008

San Antonio,

TX

University of Texas Health Science Center at San Antonio

Adipose Aromatase Expression and Breast Cancer

Hannah

M.

Linden,

M.D.

2008

Seattle,

WA

University of Washington

Quantitative in Vivo Pharmacodynamics of Breast Cancer Endocrine Therapy using PET Estrogen Receptor Imaging

M.

Peter

Marinkovich,

M.D.

2008

Stanford,

CA

Stanford University School of Medicine

Tumor specific Laminin precursor domains in cervical carcinoma

John

I.

Risinger,

Ph.D.

2008

Macon,

GA

Mercer University

Characterization of the PSPHL gene preferentially overexpressed in gynecologic cancers from African Americans

Carol

L.

Rosenberg,

M.D.

2008

Boston,

MA

Boston University, BUMC

Copy Number Variation (CNV) in the initiation and progression of breast cancer

Pepper

Schedin

Ph.D.

2008

Aurora

CO

University of Colorado at Denver & Health Sciences Center

Role of Macrophages in the Metastatic Spread of Pregnancy-Associated Breast Cancer

Toni

M.

Antalis,

Ph.D.

2007

Baltimore,

MD

University of Maryland School of Medicine

Targeting Testisin as a Therapy for Ovarian Cancer

Ronald

J.

Buckanovich,

Ph.D.

2007

Ann Arbor,

MI

University of Michigan Cancer Center

CD14+ Vascular Leukocytes in Ovarian Cancer: Their Role in Angiogenesis, Prognosis and Therapeutics in Ovarian Cancer

Concepcion

R.

Diaz-Arrastia,

M.D.

2007

Galveston,

TX

University of Texas Medical Branch Galveston

Development of a Genomic Profile For The Progression of Cervical Intraepithelial Neoplasia

James

M.

Ford,

M.D.

2007

Stanford,

CA

Stanford University School of Medicine

A Novel Approach to Identify Chemoprevention Agents for BRCA1-associated Malignancies

Naomi

J.

Halas,

Ph.D.

2007

Houston,

TX

William Marsh Rice University

Nanoengineered Vectors for Targeted Delivery-Triggered Release of Gene Therapies for Ovarian, Breast, Cervical and Uterine Cancers

Patricia

J.

Keely,

Ph.D.

2007

Madison,

WI

University of Wisconsin at Madison

Analysis of Collagen Signatures to Determine Breast Cancer Progression in Clinical Samples

Ralph

P.

Mason,

Ph.D.

2007

Dallas,

TX

UT Southwestern Medical Center at Dallas

Predicting Treatment Response for Cervical Cancer: Non-Invasive Assessment Using BOLD MRI

Dan

Mercola,

M.D., Ph.D.

2007

Irvine,

CA

The Regents of the University of California

Development of a Diagnostic and Prognostic Test for Breast Cancer Based on DNA Methylation Signature

Ben

Ho

Park,

M.D.

2007

Baltimore,

MD

Johns Hopkins University

Mutational Somatic Cell Engineering for Breast Cancer Therapy

Antoni

Ribas,

M.D.

2007

Los Angeles,

CA

University of California Los Angeles (UCLA)

Immunotherapy of Cervical Cancer with Helper Dependent Adenovirus-Epstein-Barr Virus (HAD-EBV) Hybrid Vectors

Shiladitya

Sengupta,

Ph.D.

2007

Cambridge,

MA

Brigham and Women's Hospital

Polyvalent Nanoparticles for Targeting Breast Cancer

Dipali

Sharma,

Ph.D.

2007

Atlanta,

GA

Emory University

Adiponectin as a Protective Adipocytokine Against Leptin Signaling in Breast Tumorigenesis

Lin

Zhang,

Ph.D.

2007

Philadelphia,

PA

Trustees of the University of Pennsylvania

The Function of MicroRNA in Ovarian Cancer

Peter

D.

Adams,

Ph.D.

2006

Philadelphia,

PA

Institute for Cancer Research

Identification of novel genetic mutations in breast cancer that predict a favorable clinical response to the new anti-cancer therapeutic, SAHA

William

E.

Carson,

M.D.

2006

Columbus,

OH

The Ohio State University Research Foundation

A Phase 1 Trial of IL-21 in Combination with Weekly Paclitaxel and Trastuzumab in Patients with HER2-Positive Malignancies

Terry

Van

Dyke,

Ph.D.

2006

Chapel Hill,

NC

University of North Carolina at Chapel Hill

A mouse model of human ovarian cancer for mechanistic, diagnostic, and therapeutic discovery

Brittney-Shea

Herbert,

Ph.D.

2006

Indianapolis,

IN

Indiana University Cancer Center

Targeting Telomerase in Breast Cancer Stem Cells: Inhibition of Breast Tumor Recurrence and Metastasis

Maria

Jasin,

Ph.D.

2006

New York,

NY

Memorial Sloan-Kettering Cancer Center

DNA repair defects and ovarian cancer development

David

Kurnit,

M.D., Ph.D.

2006

Ann Arbor,

MI

The Regents of the University of Michigan

Detection of cervical dysplasia and cancer by MassARRAY detection of human papilloma virus

John

A.

Martignetti,

M.D., Ph.D.

2006

New York,

NY

Mount Sinai School of Medicine

Inhibition of KLF6-SV1: Targeting Ovarian Cancer Spread and Survival

Vered

Stearns,

M.D.

2006

Baltimore,

MD

Kimmel Cancer Center at Johns Hopkins

Intraductal therapy for breast cancer treatment and prevention

Sheila

A.

Stewart,

Ph.D.

2006

St. Louis,

MO

Washington University

Stromal Factors and Tumorigenesis

Theresa

V.

Strong,

Ph.D.

2006

Birmingham,

AL

The University of Alabama at Birmingham

The Role of Sp17 in Tumor Development

Muneesh

Tewari,

M.D., Ph.D.

2006

Seattle,

WA

Fred Hutchinson Cancer Research Center

An Integrated Functional Genomic Approach to Identify Cisplatin Resistance Determinants in Ovarian Cancer

Michael

A.

White,

Ph.D.

2006

Dallas,

TX

U.T. Southwestern Medical Center

Harnessing Genome-wide RNAi to Guide Rational Design of Combinatorial Chemotherapies Targeting Ovarian Cancer

Hua

Zhao,

Ph.D.

2006

Buffalo,

NY

Health Research, Inc.

Pharmocogenetic Profiles to Predict Response to Chemotherapy in Ovarian Cancer

Robert

Benezra,

Ph.D.

2005

New York,

NY

Memorial Sloan-Kettering Cancer Center

Targeted anti-angiogenic therapy with peptide conjugated antisense oligonucleotides (PCAOs)

Diego

H.

Castrillon,

M.D., Ph.D.

2005

Dallas,

TX

The University of Texas Southwestern Medical Center

Roles of FoxO Transcription Factors in Endometrial Cancer

William

Cliby,

M.D.

2005

Rochester,

MN

Mayo Clinic

ATR is a mutational target in endometrial cancers: opportunities for a novel therapeutic advantage

James

DiRenzo,

Ph.D.

2005

Hanover,

NH

Dartmouth Medical School

Evaluation of Genetic Pathways Underlying Stem Cell Renewal as Predictors of Early Malignancy in Breast Cancer

Suzanne

Fuqua,

Ph.D.

2005

Houston,

TX

Baylor College of Medicine

Dual Specificity Phosphatase 6 and Tamoxifen Resistance

Theresa

A.

Guise,

M.D.

2005

Charlottesville,

VA

University of Virginia, Division of Endocrinology

Inhibition of Breast Cancer Bone Metastasis with Anti-Hypoxic Treatment

Leaf

Huang,

Ph.D.

2005

Chapel Hill,

NC

University of North Carolina

Therapeutic Vaccine for Cervical Cancer

Michael

M.

Ouellette,

Ph.D.

2005

Omaha,

NE

University of Nebraska Medical Center

Novel Strategies for the Inhibition of Telomerase in Breast Cancer cells

Richard

Roden,

Ph.D.

2005

Baltimore,

MD

Johns Hopkins School of Medicine

Vaccination against cervical cancer

Toshiyasu

Taniguchi,

M.D., Ph.D.

2005

Seattle,

WA

Fred Hutchinson Cancer Research Center

Sensitization of Ovarian Cancer Cells to Chemotherapy by Modulating the Fanconi Anemia-BRCA Pathway

Richard

Bankert,

Ph.D.

2004

Buffalo,

NY

State University of New York at Buffalo

Breast Cancer Vaccine Designed to Eradicate Both Primary and Metastatic Tumors and Generate a Prolonged Anti-Tumor Immunity

Sharon

B.

Cantor,

Ph.D.

2004

Worcester,

MA

University of Massachusetts Medical School

BRCA1 Associated BACH1 Helicase as a Biomarker for Breast Cancer

Sudhansu

K.

Dey,

Ph.D.

2004

Nashville,

TN

Vanderbilt University Medical Center

Cyclooxygenase-1 is a Target for Ovarian Cancer Prevention and Treatment

Leif

W.

Ellisen,

Ph.D.

2004

Boston,

MA

The General Hospital Corporation

P53 Family Members in Refractory Breast Cancers

William

K.

Holloman,

Ph.D.

2004

New York,

NY

Weill Medical College of Cornell University

Novel Screen for BRCA2-deficiency Chemopreventive Drugs

Robert

B.

Jaffe,

M.D.

2004

San Francisco,

CA

UCSF Comprehensive Cancer Center

VEGF-Trap + Paclitaxel to Reduce Tumor Burden & Ascites in Ovarian Cancer

Alessandro

D.

Santin,

M.D.

2004

Little Rock,

AR

University of Arkansas for Medical Sciences

Therapy with Clostridium Perfringens Enterotoxin (CPE) for Chemotherapy Resistant Ovarian Cancer

Richard

Schlegel,

M.D., Ph.D.

2004

Washington,

DC

Georgetown University Medical School

A Topical Drug Treatment for Early Cervical Cancer

Victoria

L.

Seewaldt,

M.D.

2004

Durham,

NC

Duke University School of Medicine

Defining the Role of RARbeta2 and CBP in Mammary Hyperplasia: A Bench to Bedside Model of Breast Cancer Risk and Prevention

Ann

D.

Thor,

M.D.

2004

Aurora,

CO

The University of Colorado At Denver

Mechanism of E2 Activation by Thyroid Hormone in Breast Cancer Cells

Carlos

L.

Arteaga,

M.D.

2003

Nashville,

TN

Vanderbilt University Medical Center

Mechanisms of Resistance to Aromatase Inhibitors in Breast Cancer

George

Coukos,

M.D., Ph.D.

2003

Philadelphia,

PA

Trustees of the University of Pennsylvania

Immunotherapy of Ovarian Cancer

David

A.

Frank,

M.D., Ph.D.

2003

Boston,

MA

Dana-Farber Cancer Institute

STAT5 Isoforms in the Pathogenesis of Breast Cancer: Differential Effects of Nearly Identical Transcription Factors

Thomas

F.

Franke,

M.D., Ph.D.

2003

New York,

NY

Columbia University in the City of New York, Dept. of Pharmacology

Therapeutic Targets Downstream of AKT Kinases

Scott

Goode,

Ph.D.

2003

Houston,

TX

Baylor College of Medicine

Potent Suppressors of Tumorogenesis

Carol

A.

Lange,

Ph.D.

2003

Minneapolis,

MN

University of Minnesota Cancer Center

A Novel Kinase Target in Breast Cancer Cells

Susan

J.

Littman,

M.D., M.S

2003

Durham,

NC

Duke University Medical Center

The Breast Cancer Susceptibility Gene, BRCA2: Isolation and Study of its Biological Activity in DNA Repair.

Karen

M.

Lounsbury,

Ph.D.

2003

Burlington,

VT

The University of Vermont, College of Medicine

Interleukin-6 as a Regulator of Angiogenesis in Ovarian Cancer

Matthew

M.

Ames,

Ph.D.

2002

Rochester

MN

Mayo Clinic

Mechanisms of Aminoflavone Selective Cytotoxicity

Nancy

Carrasco,

M.D.

2002

Bronx,

NY

Albert Einstein College of Medicine

Diagnosis and Targeted Radioiodide Therapy in Breast Cancer

Arul

M.

Chinnaiyan,

M.D., Ph.D.

2002

Ann Arbor,

MI

University of Michigan, Department of Pathology

Development of Breast Cancer Biomarkers Using DNA and Protein Microarray Technologies

Gilbert

Chu,

M.D., Ph.D.

2002

Stanford,

CA

Stanford University School of Medicine

Predicting Breast Cancer Risk from Microarrays

John

D.

Minna,

M.D.

2002

Dallas,

TX

U.T. Southwestern Medical Center at Dallas

Development of RNAi technology to knock down the expression of genes potentially important in the pathogenesis of human breast, ovarian, and cervical cancer

Eric

J.

Stanbridge,

Ph.D.

2002

Irvine,

CA

University of California, Irvine

Molecular Genetic Analysis of Cervical Cancer Progression

Ajay

Verma,

M.D., Ph.D.

2002

Bethesda,

MD

Uniformed Services University of the Health Sciences

Erythropoietin Signaling in Cervical Cancer

homecausesgiveeventsblog
donate now